لاتفيا - اللاتفية - Pārtikas un veterinārais dienests, Zemkopības ministrija

fatro s.p.a., itālija - a-tokoferola acetāts d-l acetylmethionine,l-karnitīna hidrohlorīds,ciānkobalamīns - šķīdums injekcijām - aitas; cūkas; liellopi; zirgi

الاتحاد الأوروبي - اللاتفية - EMA (European Medicines Agency)

pfizer europe ma eeig - tofacitinibs - artrīts, reimatoīds - imūnsupresanti - rheumatoid arthritistofacitinib in combination with methotrexate (mtx) is indicated for the treatment of moderate to severe active rheumatoid arthritis (ra) in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying antirheumatic drugs (dmards) (see section 5. tofacitinib can be given as monotherapy in case of intolerance to mtx or when treatment with mtx is inappropriate (see sections 4. 4 un 4. psoriatic arthritistofacitinib in combination with mtx is indicated for the treatment of active psoriatic arthritis (psa) in adult patients who have had an inadequate response or who have been intolerant to a prior disease modifying antirheumatic drug (dmard) therapy (see section 5. ulcerative colitistofacitinib is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (uc) who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent (see section 5. tofacitinib is indicated for the treatment of active polyarticular juvenile idiopathic arthritis (rheumatoid factor positive [rf+] or negative [rf-] polyarthritis and extended oligoarthritis), and juvenile psoriatic arthritis (psa) in patients 2 years of age and older, who have responded inadequately to previous therapy with disease modifying antirheumatic drugs (dmards). tofacitinib can be given in combination with methotrexate (mtx) or as monotherapy in case of intolerance to mtx or where continued treatment with mtx is inappropriate. ankylosing spondylitistofacitinib is indicated for the treatment of adult patients with active ankylosing spondylitis (as) who have responded inadequately to conventional therapy.

لاتفيا - اللاتفية - Zāļu valsts aģentūra

omega pharma baltics, sia, latvija - magnija lactas dihydricus, pyridoxini hydrochloridum - zarnās šķīstošā tablete - 48 mg/5 mg

لاتفيا - اللاتفية - Zāļu valsts aģentūra

omega pharma baltics, sia, latvija - magnija, pyridoxini hydrochloridum - zarnās šķīstošās tabletes - 48 mg/5 mg

لاتفيا - اللاتفية - Zāļu valsts aģentūra

teva pharmaceuticals bulgaria eood, bulgaria - piridostigmīna bromīds - tabletes - 60 mg

لاتفيا - اللاتفية - Zāļu valsts aģentūra

angelini pharma polska sp.z o.o., poland - magnija lactas dihydricus, pyridoxini hydrochloridum - zarnās šķīstošā tablete - 48 mg/5 mg

لاتفيا - اللاتفية - Zāļu valsts aģentūra

sandoz d.d., slovenia - vankomicīns - pulveris infūziju šķīduma pagatavošanai - 1000 mg

لاتفيا - اللاتفية - Zāļu valsts aģentūra

lek pharmaceuticals d.d., slovenia - amoxicillinum, skābes clavulanicum - apvalkotā tablete - 875 mg/125 mg

لاتفيا - اللاتفية - Pārtikas un veterinārais dienests, Zemkopības ministrija

huvepharma nv, beļģija - aknas (kā aknas tartrāta) - pulveris iekšķīgi lietojama šķīduma pagatavošanai - 500 mg/g - cūkas; teļi; tītari; vistas

لاتفيا - اللاتفية - Zāļu valsts aģentūra

fresenius kabi polska sp.z o.o., poland - vankomicīns - pulveris infūziju šķīduma koncentrāta pagatavošanai - 1000 mg